• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞衍生的纳米囊泡作为用于药物递送目的的外泌体模拟物:用途和建议。

Cell-Derived Nanovesicles as Exosome-Mimetics for Drug Delivery Purposes: Uses and Recommendations.

机构信息

Department of Pharmacy, National University of Singapore, Singapore, Singapore.

NUS Graduate School for Integrative Sciences and Engineering, Centre for Life Sciences (CeLS), Singapore, Singapore.

出版信息

Methods Mol Biol. 2021;2211:147-170. doi: 10.1007/978-1-0716-0943-9_11.

DOI:10.1007/978-1-0716-0943-9_11
PMID:33336276
Abstract

Cell-derived Drug Delivery Systems (DDSs), particularly exosomes, have grown in popularity and have been increasingly explored as novel DDSs, due to their intrinsic targeting capabilities. However, clinical translation of exosomes is impeded by the tedious isolation procedures and poor yield. Cell-derived nanovesicles (CDNs) have recently been produced and proposed as exosome-mimetics. Various methods for producing exosome-mimetics have been developed. In this chapter, we present a simple, efficient, and cost-effective CDNs production method that uses common laboratory equipment (microcentrifuge) and spin cups. Through a series of extrusion and size exclusion steps, CDNs are produced from in vitro cell culture and are found to highly resemble the endogenous exosomes. Thus, we envision that this strategy holds great potential as a viable alternative to exosomes in the development of ideal DDS.

摘要

细胞衍生的药物递送系统(DDS),特别是外泌体,由于其内在的靶向能力,越来越受到关注,并被越来越多地探索作为新型 DDS。然而,外泌体的临床转化受到繁琐的分离程序和低产量的阻碍。细胞衍生的纳米囊泡(CDNs)最近已经被生产出来,并被提议作为外泌体模拟物。已经开发了各种生产外泌体模拟物的方法。在本章中,我们提出了一种简单、高效和具有成本效益的 CDNs 生产方法,该方法使用常见的实验室设备(微量离心机)和旋转杯。通过一系列挤压和大小排除步骤,从体外细胞培养中产生 CDNs,并且发现它们非常类似于内源性外泌体。因此,我们设想,这种策略作为理想 DDS 中替代外泌体的可行方法具有很大的潜力。

相似文献

1
Cell-Derived Nanovesicles as Exosome-Mimetics for Drug Delivery Purposes: Uses and Recommendations.细胞衍生的纳米囊泡作为用于药物递送目的的外泌体模拟物:用途和建议。
Methods Mol Biol. 2021;2211:147-170. doi: 10.1007/978-1-0716-0943-9_11.
2
Bioinspired Cell-Derived Nanovesicles versus Exosomes as Drug Delivery Systems: a Cost-Effective Alternative.仿生细胞衍生的纳米囊泡与外泌体作为药物传递系统:一种具有成本效益的替代方案。
Sci Rep. 2017 Oct 30;7(1):14322. doi: 10.1038/s41598-017-14725-x.
3
Exosomes: Cell-Derived Nanoplatforms for the Delivery of Cancer Therapeutics.外泌体:用于递呈癌症治疗药物的细胞衍生纳米平台。
Int J Mol Sci. 2020 Dec 22;22(1):14. doi: 10.3390/ijms22010014.
4
RNAi delivery by exosome-mimetic nanovesicles - Implications for targeting c-Myc in cancer.外泌体模拟纳米囊泡介导的 RNAi 递呈 - 靶向癌症中 c-Myc 的意义。
Biomaterials. 2016 Sep;102:231-8. doi: 10.1016/j.biomaterials.2016.06.024. Epub 2016 Jun 15.
5
Microvesicles: Isolation, Characterization for In Vitro and In Vivo Procedures.微囊泡:体外和体内操作的分离、表征
Methods Mol Biol. 2016;1372:181-92. doi: 10.1007/978-1-4939-3148-4_14.
6
Exosome-like Nanoparticles: A New Type of Nanocarrier.外泌体样纳米颗粒:一种新型纳米载体。
Curr Med Chem. 2020;27(23):3888-3905. doi: 10.2174/0929867326666190129142604.
7
Engineering of Cell Derived-Nanovesicle as an Alternative to Exosome Therapy.工程化细胞衍生纳米囊泡作为外泌体治疗的替代方法。
Tissue Eng Regen Med. 2024 Jan;21(1):1-19. doi: 10.1007/s13770-023-00610-4. Epub 2023 Dec 8.
8
[Contamination of exosome preparations, isolated from biological fluids].[从生物流体中分离的外泌体制剂的污染情况]
Biomed Khim. 2017 Jan;63(1):91-96. doi: 10.18097/PBMC2017630191.
9
Toward the next-generation phyto-nanomedicines: cell-derived nanovesicles (CDNs) for natural product delivery.迈向新一代植物-纳米药物:用于天然产物递送的细胞衍生纳米囊泡 (CDNs)。
Biomed Pharmacother. 2022 Jan;145:112416. doi: 10.1016/j.biopha.2021.112416. Epub 2021 Nov 12.
10
Cell-derived nanovesicle-mediated drug delivery to the brain: Principles and strategies for vesicle engineering.细胞衍生的纳米囊泡介导的脑内药物递送:囊泡工程的原理和策略。
Mol Ther. 2023 May 3;31(5):1207-1224. doi: 10.1016/j.ymthe.2022.10.008. Epub 2022 Oct 17.

引用本文的文献

1
Exosomes as Therapeutic and Diagnostic Tools: Advances, Challenges, and Future Directions.外泌体作为治疗和诊断工具:进展、挑战与未来方向
Cell Biochem Biophys. 2025 Mar 24. doi: 10.1007/s12013-025-01730-5.
2
Mechanisms of extracellular vesicle uptake and implications for the design of cancer therapeutics.细胞外囊泡摄取机制及其对癌症治疗设计的影响。
J Extracell Biol. 2024 Oct 30;3(11):e70017. doi: 10.1002/jex2.70017. eCollection 2024 Nov.
3
Tailoring biomaterials for vaccine delivery.为疫苗传递量身定制生物材料。

本文引用的文献

1
Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications.比较不同方法提取培养上清液中外泌体的产量、纯度和下游应用效果。
Sci Rep. 2019 Mar 29;9(1):5335. doi: 10.1038/s41598-019-41800-2.
2
Human Cancer Cell Membrane-Coated Biomimetic Nanoparticles Reduce Fibroblast-Mediated Invasion and Metastasis and Induce T-Cells.人源癌细胞膜包覆仿生纳米颗粒减少成纤维细胞介导的侵袭和转移并诱导 T 细胞。
ACS Appl Mater Interfaces. 2019 Feb 27;11(8):7850-7861. doi: 10.1021/acsami.8b22309. Epub 2019 Feb 14.
3
Autologous cancer cell-derived extracellular vesicles as drug-delivery systems: a systematic review of preclinical and clinical findings and translational implications.
J Nanobiotechnology. 2024 Aug 12;22(1):480. doi: 10.1186/s12951-024-02758-0.
4
T-cell immunity against senescence: potential role and perspectives.T 细胞对衰老的免疫:潜在作用和展望。
Front Immunol. 2024 Mar 5;15:1360109. doi: 10.3389/fimmu.2024.1360109. eCollection 2024.
5
Research Advances of Engineered Exosomes as Drug Delivery Carrier.工程外泌体作为药物递送载体的研究进展
ACS Omega. 2023 Nov 9;8(46):43374-43387. doi: 10.1021/acsomega.3c04479. eCollection 2023 Nov 21.
6
Opportunities and challenges of natural killer cell-derived extracellular vesicles.自然杀伤细胞衍生的细胞外囊泡的机遇与挑战
Front Bioeng Biotechnol. 2023 Mar 31;11:1122585. doi: 10.3389/fbioe.2023.1122585. eCollection 2023.
7
Extracellular vesicles, the emerging mirrors of brain physiopathology.细胞外囊泡,大脑病理生理学的新兴镜像。
Int J Biol Sci. 2023 Jan 1;19(3):721-743. doi: 10.7150/ijbs.79063. eCollection 2023.
8
Extracellular vesicles as a novel photosensitive drug delivery system for enhanced photodynamic therapy.细胞外囊泡作为一种新型的光敏药物递送系统用于增强光动力疗法。
Front Bioeng Biotechnol. 2022 Sep 27;10:1032318. doi: 10.3389/fbioe.2022.1032318. eCollection 2022.
9
Manufacturing Therapeutic Exosomes: from Bench to Industry.治疗性外泌体的制造:从实验室到产业化。
Mol Cells. 2022 May 31;45(5):284-290. doi: 10.14348/molcells.2022.2033.
自体癌细胞衍生的细胞外囊泡作为药物递送系统:临床前和临床发现及转化意义的系统评价。
Nanomedicine (Lond). 2019 Feb;14(4):493-509. doi: 10.2217/nnm-2018-0286. Epub 2019 Jan 29.
4
Exosomes and miRNA-Loaded Biomimetic Nanovehicles, a Focus on Their Potentials Preventing Type-2 Diabetes Linked to Metabolic Syndrome.外泌体和 miRNA 负载仿生纳米载体,关注其预防代谢综合征相关 2 型糖尿病的潜力。
Front Immunol. 2018 Nov 21;9:2711. doi: 10.3389/fimmu.2018.02711. eCollection 2018.
5
Targeted cancer therapy using engineered exosome as a natural drug delivery vehicle.使用工程化外泌体作为天然药物递送载体的靶向癌症治疗。
Onco Targets Ther. 2018 Sep 12;11:5753-5762. doi: 10.2147/OTT.S173110. eCollection 2018.
6
Comparison of exosome-mimicking liposomes with conventional liposomes for intracellular delivery of siRNA.外泌体模拟脂质体与传统脂质体用于 siRNA 的细胞内递送的比较。
Int J Pharm. 2018 Oct 25;550(1-2):100-113. doi: 10.1016/j.ijpharm.2018.08.040. Epub 2018 Aug 20.
7
Novel alternatives to extracellular vesicle-based immunotherapy - exosome mimetics derived from natural killer cells.基于细胞外囊泡的免疫疗法的新型替代物 - 源自自然杀伤细胞的外泌体模拟物。
Artif Cells Nanomed Biotechnol. 2018;46(sup3):S166-S179. doi: 10.1080/21691401.2018.1489824. Epub 2018 Aug 9.
8
Modification of Extracellular Vesicles by Fusion with Liposomes for the Design of Personalized Biogenic Drug Delivery Systems.通过与脂质体融合来修饰细胞外囊泡,设计个性化的生物源药物传递系统。
ACS Nano. 2018 Jul 24;12(7):6830-6842. doi: 10.1021/acsnano.8b02053. Epub 2018 Jul 10.
9
A Novel Strategy to Increase the Yield of Exosomes (Extracellular Vesicles) for an Expansion of Basic Research.一种提高外泌体(细胞外囊泡)产量以拓展基础研究的新策略。
Biol Pharm Bull. 2018;41(5):733-742. doi: 10.1248/bpb.b17-00919.
10
Progress and challenges towards targeted delivery of cancer therapeutics.癌症治疗靶向递药的进展与挑战。
Nat Commun. 2018 Apr 12;9(1):1410. doi: 10.1038/s41467-018-03705-y.